I'm not following that closely. Among those that do, it was felt that the program was likely to disappoint. There is an article from STAT for those that subscribe.
Updated with comments from CEO Vlad Coric: $BHVN Biohaven protein-degrader drug falls short of investor expectations in early-study test https://t.co/D6rPMy3lS3
— Adam Feuerstein ✡️ (@adamfeuerstein) May 29, 2024
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.